Gómez-Lumbreras, Ainhoa http://orcid.org/0000-0002-3916-0402
Garcia Sangenis, Ana
Prat Vallverdú, Oriol
Gatell Carbó, Anna
Vedia Urgell, Cristina
Gisbert Gustemps, Laura
Bruna Pérez, Xavier
Ramos Quiroga, Antoni
Morros Pedrós, Rosa
Funding for this research was provided by:
Departament de Salut, Generalitat de Catalunya (SLT006/17/00309)
Article History
Received: 17 June 2020
Accepted: 1 March 2021
First Online: 10 March 2021
Declarations
:
: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article:L.G.G. received travel awards for taking part in psychiatric meetings from Shire in the last 3 years.J.A.R.-Q. was on the speakers’ bureau and/or acted as a consultant for Eli Lilly, Janssen-Cilag, Novartis, Shire, Lundbeck, Almirall, Braingaze, Sincrolab and Rubió in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire and Eli Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following pharmaceutical companies in the last 5 years: Eli Lilly, Lundbeck, Janssen-Cilag, Actelion, Shire, Ferrer and Rubió.The rest of the authors have no conflicts of interest relevant to this article to disclose.